A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants

Neurodegenerative Diseases Clinical Trial

Official title:

A Randomised, Double Blind, Placebo Controlled, Single Centre, Three-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2808 in Healthy Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04578028
• Other study ID #: ONO-2808-01
• Secondary ID: 2019-004693-26
• Status: Completed
• Phase: Phase 1
• Start date: August 19, 2020
• Est. completion date: October 7, 2021

Study information

• Verified date: December 2021
• Source: Ono Pharmaceutical Co. Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first in human study to determine the safety, tolerability and pharmacokinetics of ONO-2808 in healthy adult participants. The study will be conducted in 3 parts: Part A, a single-ascending dose part with an assessment of the potential food effects in non-Japanese adult participants; Part B, a single dose part to assess the effect of age in non-Japanese elderly participants; and Part C, a multiple-ascending dose part with ONO-2808 administered to healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 94
• Est. completion date: October 7, 2021
• Est. primary completion date: August 26, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Able to provide fully informed written consent.

2. 18-55 years (Part A & C) or =65 years (Part B).

3. Male and female participants (Women of non-child bearing potential (WONCBP)).

4. Agree to use an effective method of contraception.

5. No clinically significant medical history and no abnormal physical examination, laboratory profiles, vital signs or ECG abnormalities, based on the Screening examination.

6. Body mass index (BMI) of =18.5 to <30 kg/m2 and a body weight of at least 50 kg for males and 45 kg for females to a maximum of 100 kg, at the time of screening.

7. Estimated Creatinine Clearance (CrCL, Cockcroft-Gault equation) =90 mL/min at Screening. In Part B only, an estimated CrCL of =60mL/min at Screening.

Exclusion Criteria:

1. Mentally or legally incapacitated or with significant emotional problems at the time of the Screening visit or expected during the conduct of the study.

2. History or presence of clinically significant medical, surgical or psychiatric condition (including history of suicidal behaviour) or objection by General Practitioner (GP) to participant entering trial.

3. Liver chemistry values above the upper limit of normal (ULN) at Screening or admission.

4. Sensitivity to the study drug.

5. Female who is pregnant or lactating or of childbearing potential.

6. History or presence of alcoholism or drug/chemical/substance abuse.

7. Evidence of poor venous access as assessed by PI.

8. Use of any medication which may affect ONO-2808 pharmacokinetics or pharmacodynamics

9. Current smoker or has smoked (including use of tobacco and/or nicotine-containing products) in the previous 3 months

10. Positive urine drugs of abuse, cotinine or alcohol results at Screening or admission.

11. Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).

12. Supine resting blood pressure less than 90/40 millimeter of mercury (mmHg) or greater than 140/90 mmHg (Part A& C) and less than 90/40 mmHg or greater than 160/90 mmHg (Part B).

13. Supine resting pulse rate lower than 40 beats per minute (bpm) or higher than 100 bpm.

14. Clinically significant history or presence of ECG findings at screening.

15. Use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days or five half-lives (whichever is longer) of first dosing and throughout the study.

16. Consumption or intake of compounds, food or fluids that are known to be a substrate, inducer or inhibitor of CYP450 for 28 days prior to the first dosing and throughout the study.

17. Donation of blood or significant blood loss within 56 days prior to the first dosing, or plasma donation within 7 days prior to the first dosing.

18. Participation in another clinical study within the last 3 months (or 5 half-lives of the study drug, whichever is longer) prior to the first dosing.

19. Objection by PI

20. Participants who are not willing to eat a high fat breakfast

Exclusion criteria, applicable to all participants undergoing lumbar puncture for CSF collection (Part A & C):

21. History of significant back pain, significant kyphosis and or scoliosis or other spinal column deformities.

22. History or evidence of fundoscopy suggestive of raised intracranial pressure.

23. History or presence of any allergy or contraindication to the local anaesthetic required for participants undergoing lumbar puncture.

Related Conditions & MeSH terms

• Neurodegenerative Diseases

Intervention

Drug:
• ONO-2808
Investigational drug
• Placebo
Placebo drug

Locations

Country	Name	City	State
United Kingdom	Parexel International Early Phase Clinical Unit (EPCU)	London

Sponsors (2)

Lead Sponsor	Collaborator
Ono Pharmaceutical Co. Ltd	Parexel

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment emergent adverse events (TEAEs) by severity.	Number of participants with TEAEs. An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possible causal relationship.	Part A and B: up to day 7; Part C: up to 17 days.
Primary	Serious adverse events (SAEs)	Number of participants with SAEs. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged hospitalization, life-threatening experience or persistent disability.	Part A and B: up to day 7; Part C: up to 17 days.
Primary	Vital signs	Summary statistics of vital signs and number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate, and blood pressure	Part A and B: up to day 7; Part C: up to 17 days
Primary	ECG parameters	Number of participants with ECG abnormalities	Part A and B: up to day 7; Part C: up to 17 days.
Primary	Clinical laboratory tests	Number of participants with clinical laboratory abnormalities (including haematology, clinical chemistry and urinalysis)	Part A and B: up to day 7; Part C: up to 17 days
Primary	Physical examination	Number of participants with physical examination abnormalities	Part A and B: up to day 7; Part C: up to 17 days
Primary	Neurological examination	Number of participants with neurological examination abnormalities	Part A and B: up to day 7; Part C: up to 17 days.
Primary	Number of participants with suicidal behaviour	Treatment-emergent suicidal ideation and behaviour will be monitored by using the Columbia Suicide Severity Rating Scale (C-SSRS) and reported.	Part C: up to 17 days
Secondary	Pharmacokinetics (Cmax)	Assessment of the maximum observed plasma concentration of ONO-2808	Part A & B: Day 1 through Day 7, Part C: Day 1 and 14
Secondary	Pharmacokinetics (Tmax)	Assessment of the time to reach Tmax for ONO-2808	Part A & B: Day 1 through Day 7, Part C: Day 1 and 14
Secondary	Pharmacokinetics (AUClast)	Assessment of the area under the concentration-time curve of ONO-2808 to last measurable concentration	Part A & B: Day 1 through Day 7
Secondary	Pharmacokinetics (AUCinf)	Assessment of the area under the concentration-time curve of ONO-2808 extrapolated to infinite time in plasma	Part A & B: Day 1 through Day 7
Secondary	Pharmacokinetics (AUCtau)	Assessment of the area under the concentration-time curve of ONO-2808 during the dosing interval in plasma	Part C: Day 1 and Day 14
Secondary	Pharmacokinetics (T1/2)	Assessment of the terminal elimination half-time of ONO-2808 in plasma	Part A & B: Day 1 through Day 7
Secondary	Pharmacokinetics (CL/F)	Assessment of the apparent clearance of ONO-2808 from plasma	Part A & B: Day 1 through Day 7
Secondary	Pharmacokinetics (Vz/F)	Assessment of the apparent volume of distribution of ONO-2808 during terminal elimination phase	Part A & B: Day 1 through Day 7
Secondary	Pharmacokinetics (Aetz)	Assessment of the amount of ONO-2808 excreted in urine over the period of sample collection	Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14
Secondary	Pharmacokinetics (Percentage fe)	Assessment of the cumulative percentage of orally administered ONO-2808 excreted into urine	Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14
Secondary	Pharmacokinetics (CLR)	Assessment of the renal clearance of ONO-2808 from plasma	Part A & B: Day 1 through Day 5, Part C: Day 1, 8 & 14.
Secondary	Distribution of ONO-2808 to the brain in Part A	Assessment of ONO-2808 brain distribution by measuring drug concentration in the cerebro spinal fluid (CSF)	Part A (in selected fasted cohorts): Day 1 and 2, Part C: Day 1 and Day 14